Skip to content

Effects of continuous consumption of the test food on postprandial blood glucose level in healthy Japanese: a randomized, placebo-controlled, double-blind, parallel-group comparison study

Effects of continuous consumption of the test food on postprandial blood glucose level in healthy Japanese: a randomized, placebo-controlled, double-blind, parallel-group comparison study - Effects of continuous consumption of the test food on postprandial blood glucose level in healthy Japanese

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000054038
Enrollment
90
Registered
2024-04-02
Start date
2024-04-02
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Japanese

Interventions

Duration: 12 weeks Test food: Active food 1 Duration: 12 weeks Test food: Active food 2 Duration: 12 weeks Test food: Active food 3 Duration: 12 weeks Test food: Placebo food

Sponsors

ORTHOMEDICO Inc.
Lead Sponsor
Medical Corporation Seishinkai, Takara Clinic Nerima Medical Association, Minami-machi Clinic Chiba University
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Japanese 2. Men or women 3. Adults 4. Healthy individuals 5. Individuals whose Cmax of blood glucose level after consumption of the carbohydrate load is 140-199 mg/dL at Scr

Exclusion criteria

Exclusion criteria: 1. Individuals who are undergoing medical treatment or have a medical history of malignant tumor, heart failure, and myocardial infarction 2. Individuals who have a pacemaker or an implantable cardioverter defibrillator (ICD) 3. Individuals who are currently undergoing treatment for any of the following chronic diseases: cardiac arrhythmia, liver disorder, chronic kidney disease, cerebrovascular disorder, rheumatic disease, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases 4. Individuals who cannot regularly take three meals (breakfast, lunch, and dinner) a day 5. Individuals who take dairy products such as milk and cheese at least four times a week 6. Individuals who are taking "Foods for Specified Health Uses" or "Foods with Functional Claims" 7. Individuals who are taking or using medications (including herbal medicines) and supplements 8. Individuals who are allergic to medications and/or the test food related products (particularly gelatin) 9. Individuals who are pregnant, lactating, or planning to become pregnant during this study 10. Individuals who have been enrolled in other clinical studies within the last 28 days before the agreement to participate in this study or plan to participate another study during this study 11. Individuals who are judged as ineligible to participate in this study by the physician

Design outcomes

Primary

MeasureTime frame
1. The measured value of the incremental area under the curve (IAUC) of the blood glucose level at 12 weeks after consumption (12w) [Active food 2 vs. Placebo food]

Secondary

MeasureTime frame
1. The measured values of the IAUC of blood glucose level at 12w [Active food 1 vs. Placebo food, Active food 3 vs. Placebo food] 2. The changes from screening (before consumption; Scr) of the IAUC of blood glucose level at 12w [Active food 2 vs. Placebo food, Active food 1 vs. Placebo food, Active food 3 vs. Placebo food] 3. The measured values and changes from Scr of the maximum blood concentration (Cmax) of blood glucose level at 12w [Active food 2 vs. Placebo food, Active food 1 vs. Placebo food, Active food 3 vs. Placebo food] 4. The measured values and changes from Scr of the fasting blood glucose level (before consumption of the carbohydrate load) and blood glucose level 30, 60, 90, and 120 minutes after consumption of the carbohydrate load at 12w [Active food 2 vs. Placebo food, Active food 1 vs. Placebo food, Active food 3 vs. Placebo food] 5. The measured values and changes from Scr of insulin, body fat percentage, fat mass, and muscle mass at 12w [Active food 2 vs. Placebo food, Active food 1 vs. Placebo food, Active food 3 vs. Placebo food]

Countries

Japan

Contacts

Public ContactNaoko Suzuki

ORTHOMEDICO Inc. R&D Department

nao@orthomedico.jp03-3818-0610

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026